Inve
IN ⇄ US

Aarti Pharmalabs share price & results

Aarti Pharmalabs Limited· Healthcare

Results to
Sept 2026
Latest analysed call
Q2 FY27
Ownership as of
Sept 2026

India's largest Xanthine derivatives maker and a leading small-molecule CDMO/API manufacturer for global pharma clients.

Company research is public. Sign in to keep your own companies, notes and cases.

Inve AI Signals on AARTIPHARM
Direct bridge to live research & tools watching Aarti Pharmalabs Limited
Guidance Hit Rate
17 targets · 50% hit rate 2 achieved · 13 active →
Segment Shift
Sector & Mix Compare sector growth & peers →
Reverse DCF
Implied Growth Test priced-in growth in DCF tool →
Concall & Tone
Q2 FY27 analysed Read claims, qualifiers & Q&A →

Price & Snapshot

₹928.3 +0.19% · +₹1.8

Last close 5 Nov 2026 · NSE · INR · Source: Inve

Performance +9.9% 1Y

₹0.6k₹0.7k₹0.8k₹0.9k₹1.0kNov 25Dec 25Feb 26Mar 26May 26Jun 26Aug 26Sept 26Nov 26Q2 FY26 — 11 Nov 2025Q3 FY26 — 10 Feb 2026Q4 FY26 — 26 May 2026Q1 FY27 — 10 Aug 2026Q2 FY27 — 29 Oct 2026

1Y: ₹844.6 on 4 Nov 2025 → ₹928.3. High ₹975 (6 Oct 2026), low ₹591.95 (30 Mar 2026).

Previous close
₹926.5
Market cap
₹8.4k Cr
52-week range
₹591.95 – ₹975
One year
+9.91%
Price to earnings (TTM to Sept 2026)
32.31×
Return on equity (TTM to Sept 2026)
12.64%

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue46.0 ₹ crore—Quarterly, as filedQuarter to Sept 2026Revenue from operations as filed. The year-earlier figure was zero or a loss, so no percentage is shown.
Operating margin22.0 %+4.0 pts YoYOperating profit / revenueQuarter to Sept 2026For the quarter; a change is in percentage points.
Net profit71.0 ₹ crore+153.6% YoYQuarterly, as filedQuarter to Sept 2026Profit after tax as filed.
Return on equity12.64 %−5.9 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-10.23 %−4.8 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)13.38 %−28.1 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Sept 2026

Guidance

What management said, and what became of it

2 of 4 judged targets kept · 13 open · verdicts reflect calls analysed to Q1 FY27.

Aarti Pharmalabs Limited management guidance track record on Inve: 17 targets tracked across analysed earnings calls (2 achieved, 2 missed, 13 open).

Delivering on Growth (1/1 achieved), while Operations (1 needs watch) & Capex (1 needs watch) are lagging.

TargetOriginal wordingSaidLatest callVerdict
Capex Project CommissioningCommissioned in Q1 FY26
Call transcript, Q3 FY25 · 7 Feb 2025		Q3 FY25Q1 FY27:Delayed again. New target is Q2 FY27: 'Both phases of Atali Block 1 with 440 kL reactor capacity will become fully operational in Q2 FY '27.'
Call transcript, Q1 FY27 · 10 Aug 2026		Delayed
Growth CDMO Revenue Growth30% to 40% YoY
Call transcript, Q4 FY25 · 12 May 2025		Q4 FY25Q4 FY26:Achieved 32% YoY growth for FY26 (₹276 crores vs ₹209 crores in FY25).
Call transcript, Q4 FY26 · 26 May 2026		Achieved
Operations EBITDA Growth12% to 15% YoY
Call transcript, Q4 FY25 · 12 May 2025		Q4 FY25Q4 FY26:FY26 EBITDA declined 5.14% YoY to ₹406 crores vs ₹428 crores in FY25.
Call transcript, Q4 FY26 · 26 May 2026		Missed

Source: Inve Guidance Tracker for Aarti Pharmalabs Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

2 of Aarti Pharmalabs Limited's 17 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 14 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Sector context

Sector call context

Shared sector pressures matched to this company’s latest reporting period.

Similar pressures reported by peers

Tailwind coverage is not available yet.

Similar commentary provides sector context; it does not establish a business relationship with Aarti Pharmalabs Limited. Each comparison matches a headwind disclosed by Aarti Pharmalabs Limited in the same calendar reporting quarter.

  • Costs are being passed through, but this diluted EBITDA margin by a couple of percentage…

    Topic: Raw material costs · Raw material cost · Q2 FY27

    Aarti Pharmalabs Limited reported: Costs are being passed through, but this diluted EBITDA margin by a couple of percentage points QoQ. If raw material prices fall, revenue will fall with them.

    Reporting period ended 2026-09-30

    8 other companies · Raw material cost

    Granules India Limited (GRANULES) reported (period ended 2026-09-30): Near-term challenge, but company is proactively working with customers on pricing mechanisms to pass on costs, potentially with a lag.

    Sudeep Pharma Limited (SUDEEPPHRM) reported (period ended 2026-09-30): Working capital cycle remained at 214 days due to strategic stockpiling of purified phosphoric acid and preliminary battery project raw materials.

    Concord Biotech Limited (CONCORDBIO) reported (period ended 2026-09-30): Solvent and input cost pressures caused a ~400 bps gross margin contraction in Q2 FY27, which management views as temporary and seeks to offset through internal yield and R&D efficiencies.

    Zota Health Care LImited (ZOTA) reported (period ended 2026-09-30): Gross margin fell about 150-160 bps QoQ (60.17% in Q2) because geopolitics raised input costs; MRP increases are limited to once a year per product, so recovery is expected over 3-4 quarters

    Evidence drawer

    Evidence type: Summary paraphrase

    Costs are being passed through, but this diluted EBITDA margin by a couple of percentage points QoQ. If raw material prices fall, revenue will fall with them.

    Source company: Aarti Pharmalabs Limited · Reporting period ended 2026-09-30 · Calendar quarter: Q2 FY27 · Distinct companies matched: 8

    Similar commentary provides sector context; it does not establish a business relationship.

From available earnings-call summaries. Disclosures are management statements, not independently verified transactions.

Live Summary

AARTIPHARM ₹928.3 +0.19%
Guidance Verdict (17 tracked) 2 kept · 13 open· 2 missed
AI Call Brief · Q2 FY27

Aarti Pharmalabs Limited Q2 FY27

Overview

Symbol
NSE:AARTIPHARM
Exchange
NSE
Currency
INR

What Aarti Pharmalabs Limited does

Based on the company's own presentations, annual report and earnings calls.

Aarti Pharmalabs manufactures Active Pharmaceutical Ingredients (APIs), advanced intermediates and Xanthine derivatives (caffeine, theophylline, aminophylline, etophylline), and offers CDMO/CMO services (process development plus commercial manufacture of KSMs, RSMs, intermediates and GMP APIs) to innovator and biotech companies worldwide. It is backward-integrated across most of its API value chain, giving it control over raw materials and intermediates, and its facilities are certified by USFDA, EU GMP, EDQM, KFDA and COFEPRIS, allowing it to supply regulated markets such as the US, EU and Japan. Xanthine derivatives are sold mainly to beverage makers (cola and energy drinks) and pharma/nutraceutical customers, while API and CDMO revenue comes from oncology, cardiovascular, anti-asthmatic, anti-diabetic and other therapy areas.

Segments

  • Xanthine Derivatives & Allied Products
  • API & Intermediates
  • CDMO/CMO
Manufacturing units
7 (across Dombivali, Vapi, Tarapur and Atali in Maharashtra & Gujarat)
USFDA-approved units
3
Products
220+
Global clients
500+
Export countries
50+
Employees
2,400+
Company website

How the price took the results

Moved an average of ±7.0% across the last 5 priced result releases

Close before → close after
QuarterReleaseRevenue (₹ Cr) Net profit (₹ Cr)Rev YoYBefore → AfterReaction
Q2 FY2729 Oct 2646 71—₹881.95 → ₹927.65+5.2%
Q1 FY2710 Aug 2639 76—₹685.85 → ₹823+20.0%
Q4 FY2626 May 263 61−72.7%₹732.45 → ₹694.6−5.2%
Q3 FY2610 Feb 26-20 48−200.0%₹794.75 → ₹764.4−3.8%
Q2 FY2611 Nov 25-9 28—₹766.05 → ₹771.55+0.7%

The move from the last close before each results date to the first close on or after it — the market's first read on the quarter alongside what was filed.

Your own record

Start an Inve Case for Aarti Pharmalabs Limited

Free account: one company. Everything above stays public.

Write why you follow Aarti Pharmalabs Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Quick Answers

Frequently asked questions on Aarti Pharmalabs Limited

Compiled directly from AARTIPHARM's filed financial statements, earnings call transcripts, and ownership disclosures.

How did Aarti Pharmalabs Limited (AARTIPHARM) perform in its latest reported quarter (Sept 2026)?

For the quarter ended Sept 2026, Aarti Pharmalabs Limited reported revenue of ₹46 Cr, net profit of ₹71 Cr, an operating margin of 22.0%. Diluted earnings per share stood at ₹7.88.

How is Aarti Pharmalabs Limited (AARTIPHARM) valued today, and what growth does the stock price imply?

Aarti Pharmalabs Limited (AARTIPHARM) trades at ₹928.3, with a market capitalization of ₹8.4k Cr.

Who owns Aarti Pharmalabs Limited (AARTIPHARM) — promoters, FIIs, DIIs, and mutual funds?

As of Sept 2026, Promoters hold 39.7%, FIIs hold 8.2%, DIIs hold 8.4%, Public shareholders hold 43.8%.

Learn to analyse Aarti Pharmalabs Limited

Guides on how to read this kind of business and the numbers that matter.